Crispier-Bacon

NSPR DD

Crispier-Bacon تم تحديثه   
AMEX:NSPR   None
- Product: CGuard with MicroNET for Stroke Prevention
- Stroke is 2nd Leading Cause of Death Worldwide (WHO)
- Currently Sold in 39 Countries
- Expanding to Brazil, China, and Japan
- CE Mark -- FDA Approval Ongoing
- 14 USA, 33 World Patents
- 7 Successful Clinical Trials, 4 On-going
- Becoming the New Standard of Care
- Minimally Invasive Outpatient Procedure
- The MicroNET solves the problem of dislodging artery plaque during stent placement
- New CEO Marvin Solsman (January 2020) 30yr Exp
- GE Healthcare, Cordis, and Integra
- Focused on Commercialization and International Market Development
- Company Recapitalized for Growth Preparation
- 30% Growth in Q42019
- Stroke Management is BIG Business
- $34 Billion associated with Stroke Management in USA yearly
- Consolidation past few days
- Falling wedge - - possible reversal

looking for .5c break and retest of new support
PT1 .58c
PT2 .79c
PT3 .89c
PT4 1.04
stop .44c
تعليق:
Triple bottom just formed here. Will keep this on watch. Surprised this one hasn't taken off yet.
تعليق:
Holding strong in PM.
تعليق:
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
تعليق:
Massive volume PM with PR should make this run at open.

إخلاء المسؤولية

لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.